Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antithrombotic agents in clinical practice].

A Pichard1

  • 1Cardiac Catheterization Labs, Washington Hospital Center, DC, USA.

Archives Des Maladies Du Coeur Et Des Vaisseaux
|March 24, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Realistic multi-cellular dosimetry for <sup>177</sup>Lu-labelled antibodies: model and application.

Physics in medicine and biology·2016
Same author

Status of the ion sources developments for the Spiral2 project at GANIL.

The Review of scientific instruments·2012
Same author

Development of a surface ionization source for the SPIRAL 2 project.

The Review of scientific instruments·2010
Same author

Direct 1+ --> N+ conversion of stable alkali ions using an electron cyclotron resonance ion source.

The Review of scientific instruments·2010
Same author

Latest developments at GANIL for stable and radioactive ion beam production.

The Review of scientific instruments·2010
Same author

GISELE: a resonant ionization laser ion source for the production of radioactive ions at GANIL.

The Review of scientific instruments·2010
Same journal

Radiokymographic study of the kinetics of the middle arc and the hils in the normal subject.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

A medication for angina pectoris and pre-fibrillatory conditions; 1262 F; six years of clinical experience; action mechanism.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Circulatory changes following the injection of hypertonic saline solutions; application to the study of angina pectoris.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Alterations in coronary circulation during aortic insufficiency in young subjects.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Cardio-esophageal auscultation.

Archives des maladies du coeur et des vaisseaux·2010
Same journal

Hypertensive accidents following the injection of acetylcholine.

Archives des maladies du coeur et des vaisseaux·2010
See all related articles

Bivalirudine, now FDA-approved, is replacing unfractionated heparin in cardiac catheterization, reducing bleeding complications and enzyme elevations. This shift also lowers costs by limiting the use of anti-GPIIb/IIIa agents.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Bivalirudine has gained FDA approval due to demonstrated efficacy and tolerance.
  • Bivalirudine is increasingly adopted in cardiac catheterization, replacing unfractionated heparin.

Purpose of the Study:

  • To evaluate the impact of bivalirudine adoption on clinical outcomes and procedural costs.
  • To assess the role of bivalirudine compared to unfractionated heparin in interventional cardiology.

Main Methods:

  • Observational analysis of bivalirudine use in a catheterization laboratory setting.
  • Comparison of outcomes, including bleeding complications and enzyme elevations, before and after bivalirudine implementation.

Main Results:

  • Bivalirudine use correlated with a reduction in bleeding complications.

Related Experiment Videos

  • A decreased risk of post-procedural enzyme elevations was observed with bivalirudine.
  • Systematic association with anti-GPIIb/IIIa agents was found unnecessary, reducing costs.

    • Conclusions:

    • Bivalirudine offers a favorable safety profile, reducing bleeding and enzyme rises in cardiac procedures.
    • Optimizing anticoagulant strategy with bivalirudine can lead to significant cost savings in interventional cardiology.